P. Mesquita

发表

Female Genital Tract Secretions and Semen Impact the Development of Microbicides for the Prevention of HIV and Other Sexually Transmitted Infections

B. Herold, P. Mesquita, R. Madan, 2011, American journal of reproductive immunology.

Thomsen-Friedenreich antigen expression in gastric carcinomas is associated with MUC1 mucin VNTR polymorphism.

M. Hollingsworth, C. Reis, A. Fonseca, 2005, Glycobiology.

Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties

B. Herold, P. Mesquita, Todd J. Johnson, 2013, Retrovirology.

Candidate Microbicide PPCM Blocks Human Immunodeficiency Virus Type 1 Infection in Cell and Tissue Cultures and Prevents Genital Herpes in a Murine Model

Sarah S. Wilson, R. Shattock, B. Herold, 2008, Journal of Virology.

Molecular Umbrellas: a Novel Class of Candidate Topical Microbicides To Prevent Human Immunodeficiency Virus and Herpes Simplex Virus Infections

R. Shattock, N. Cheshenko, B. Herold, 2007, Journal of Virology.

Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants

R. Shattock, P. Fletcher, P. Mesquita, 2006, Retrovirology.

Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women.

G. Doncel, C. Rollenhagen, B. Herold, 2017, AIDS research and human retroviruses.

Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus–Herpes Simplex Virus Coinfection

K. Anastos, K. Herold, B. Herold, 2016, The Journal of infectious diseases.

A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring

Y. Lo, C. Hendrix, M. Marzinke, 2016, AIDS.

Bridging the Gap between Preclinical and Clinical Microbicide Trials: Blind Evaluation of Candidate Gels in Murine Models of Efficacy and Safety

G. Doncel, Sarah S. Wilson, N. Cheshenko, 2011, PloS one.

Herpes Simplex Virus Downregulates Secretory Leukocyte Protease Inhibitor: a Novel Immune Evasion Mechanism

Sarah S. Wilson, N. Cheshenko, B. Herold, 2008, Journal of Virology.

Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data

Hugo A. Wefer, Melis N. Anahtar, R. J. Hayes, 2020, BMC Medicine.

Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges

B. Herold, J. Mcnicholl, P. Mesquita, 2013, Proceedings of the National Academy of Sciences.

A Randomized Trial to Assess Anti-HIV Activity in Female Genital Tract Secretions and Soluble Mucosal Immunity Following Application of 1% Tenofovir Gel

C. Hendrix, H. Cohen, B. Herold, 2011, PloS one.

A Compartmental Pharmacokinetic Evaluation of Long‐Acting Rilpivirine in HIV‐Negative Volunteers for Pre‐Exposure Prophylaxis

B. Gazzard, B. Herold, M. Boffito, 2014, Clinical pharmacology and therapeutics.

Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection.

B. Herold, P. Mesquita, P. Kiser, 2012, The Journal of antimicrobial chemotherapy.

Susceptibility to Genital Herpes as a Biomarker Predictive of Increased HIV Risk: Expansion of a Murine Model of Microbicide Safety

Sarah S. Wilson, N. Cheshenko, B. Herold, 2009, Antiviral therapy.

Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety.

Sarah S. Wilson, N. Cheshenko, B. Herold, 2009, The Journal of infectious diseases.

Pharmacokinetics and Safety Assessment of Anti-HIV Dapivirine Vaginal Microbicide Rings with Multiple Dosing

Joseph P. Romano, B. Herold, P. Mesquita, 2014 .

A perspective on progress and gaps in HIV prevention science.

B. Herold, P. Mesquita, P. Kiser, 2012, AIDS research and human retroviruses.

Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis

Sung Hyun Park, Jonathan T. Su, I. Szleifer, 2015, Antimicrobial Agents and Chemotherapy.

Antiviral Activity of Genital Tract Secretions After Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1

B. Richardson, J. Marrazzo, C. Hendrix, 2014, Journal of acquired immune deficiency syndromes.

Pharmacokinetic and Pharmacodynamic Evaluation following Vaginal Application of IQB3002, a Dual-Chamber Microbicide Gel Containing the Nonnucleoside Reverse Transcriptase Inhibitor IQP-0528 in Rhesus Macaques

J. Mcnicholl, P. Mesquita, K. Buckheit, 2015, Antimicrobial Agents and Chemotherapy.

Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy Women.

G. Doncel, C. Rollenhagen, B. Herold, 2016, AIDS research and human retroviruses.

Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity.

G. Doncel, R. Fichorova, B. Herold, 2015, AIDS research and human retroviruses.

Griffithsin Protects Mice from Genital Herpes by Preventing Cell-to-Cell Spread

M. Stefanidou, W. Halford, K. Palmer, 2013, Journal of Virology.

Postcoital Bioavailability and Antiviral Activity of 0.5% PRO 2000 Gel: Implications for Future Microbicide Clinical Trials

H. Cohen, B. Herold, A. Profy, 2010, PloS one.

HIV transmission models: Lessons learned for microbicide formulation design

B. Herold, P. Mesquita, 2014 .

Chronic HIV Infection Is Associated with Upregulation of Proinflammatory Cytokine and Chemokine and Alpha Defensin Gene Expression in Colorectal Mucosa.

Y. Lo, J. Elliott, P. Mesquita, 2015, AIDS research and human retroviruses.

Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.

N. Cheshenko, B. Herold, D. Fredricks, 2018, JCI insight.

Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa.

B. Herold, P. Mesquita, P. Kiser, 2013, Antiviral research.